Glucagon-like peptide 2 (GLP-2) is a 33-aa proglucagon-derived peptide produced by intestinal enteroendocrine cells. GLP-2 stimulates intestinal growth and upregulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. Moreover, GLP-2 prevents intestinal hypoplasia resulting from total parenteral nutrition. However, the mechanism underlying these actions has remained unclear. 
Glucagon-like peptides (GLPs) encoded by the proglucagon gene play key roles in glucose homeostasis, gastric emptying, insulin secretion, and appetite regulation (1) . Glucagon and GLP-1 exert their effects through distinct G protein-coupled receptors (GPCRs). In contrast, unique receptors for GLP-2, glicentin, and oxyntomodulin have not yet been identified, despite considerable attempts at receptor isolation via classical molecular biology approaches (2) . Recent studies have shown that GLP-2 is a potent intestinal growth factor that stimulates crypt cell proliferation and inhibits epithelial apoptosis (3) . GLP-2 promotes epithelial proliferation in both small and large intestine; however, the mechanisms utilized by GLP-2 for promotion of intestinal growth remain unclear.
To understand the mechanisms underlying GLP-2 action, we have carried out studies directed at the identification and cloning of the putative GLP-2 receptor. We now have isolated rat and human cDNAs encoding GLP-2-responsive GPCRs, which show highest similarity to receptors for glucagon and GLP-1. The GLP-2R is coupled to activation of adenylate cyclase, and the receptor is expressed selectively in rat hypothalamus and the gastrointestinal tract, known targets of GLP-2 action. These findings establish GLP-2 as a novel hormone that, like glucagon and GLP-1, exerts its actions through a distinct receptor expressed in a highly tissuerestricted manner. The GLP-2R should provide an important target for isolation of small molecules mimicking GLP-2 action and for future studies delineating specific mechanisms underlying GLP-2 action in the gut and central nervous system.
Methods and Materials
Primers, cDNA Libraries, and Cloning Strategy. Initial attempts at low-stringency hybridization of intestine and brain cDNA libraries using GLP-1R͞GlucagonR cDNA sequences were not successful. Two million cDNA clones from rat hypothalamus and rat duodenum͞jejunum cDNA libraries subsequently were screened with degenerate oligonucleotides derived from conserved transmembrane II and VII GPCR coding sequences: C4 -4 (5Ј-AACTACATCCACMKGM AYCTGTTYVYGTCBTTCATSCT-3Ј) (IUB nomenclature) and C9 -2R (5Ј-TCYRNCTGSACCTCMYYRT TGAS-RAARCAGTA-3Ј) (for nomenclature, see ref. 4 ). First-round cDNA plugs (1,057) were isolated in this screen. In a complementary strategy, PCR was conducted on intestinal cDNA templates by using sets of degenerate PCR primers, based on conserved transmembrane amino acid motifs from family B GPCRs or from motifs conserved mainly within the glucagon͞ glucose-dependent insulinotropic polypeptide (GIP)͞GLP-1 receptor subfamily. PCR products were Southern-blotted and probed with 32 P-end-labeled C4-4 oligonucleotide. PCRs, amplified from rat neonatal intestine cDNA (Stratagene; catalog no. 936508) were chosen for cloning. These products had been amplified with the degenerate primers M2F (5Ј-TTTTTCTAGAASRTSATSTACACNGT SGGCTAC-3Ј) (based on conserved transmembrane domain I sequences) and M7R (5Ј-TTTTCTCGAGCCARCARCCASSWRTART-TGGC-3Ј) (based on conserved transmembrane III sequences). PCR products were cloned into pBluescript, screened by filter hybridization with the nested C4-4 oligonucleotide, and sequenced, leading to the identification of a sequence fragment from a novel GPCR family B member, designated WBR, that ultimately proved to be the GLP-2R. Two new GLP-2R-specific PCR primers, P23-F1 (5Ј-TCTGACAGATATGA-CATCCATCCAC-3Ј) and P23-R1 (5Ј-TCATCTCCCTCT-TCTTGGCTCTTAC-3Ј), were used to screen the 1,057 cDNA plugs obtained by hybridization screening, leading to the The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked ''advertisement'' in accordance with 18 U.S.C. §1734 solely to indicate this fact.
PNAS is available online at www.pnas.org. identification of three independent clones, two from the duodenum͞jejunum library and a third from hypothalamus, which, together, contained a 2,537-bp cDNA insert encoding full-length rat GLP-2R.
To clone the human GLP-2R, the coding region of the rat GLP-2R was used to screen a human hypothalamus cDNA library (CLONTECH; catalog no. 1172a), from which a single positive clone (HHT13) was isolated and sequenced. A fulllength insert was ligated into pcDNA3 for expression studies.
Intestinotrophic Activity, cAMP Determination, and Radioligand-Binding Studies. For cAMP assays, an episomal stable M for 30 min in medium containing 3-isobutylmethylxanthine. The reaction was terminated with the addition of 95% ethanol and 5 mM EDTA. Aliquots of the ethanol extract were used to determine cAMP levels using an enzyme immunoassay kit (Amersham) as described by the manufacturer. Results were analyzed with GRAPHPAD PRISM software and expressed as pmol cAMP per well. For radioligand-binding assays, cells expressing GLP-2R were harvested and homogenized in 25 mM Hepes (pH 7.4) buffer containing 140 mM NaCl, 0.9 mM MgCl 2 , 5 mM KCl, 1.8 mM CaCl 2 , 17 mg/ml Diprotin A, and 100 M phenanthroline. Homogenates were centrifuged for 10 min at 1,000 ϫ g at 4°C to remove cellular debris. For saturation experiments, membranes containing 25 g protein were incubated with increasing concentrations of M) for 2 hr as described above. Reactions were terminated by centrifugation at 13,000 ϫ g for 15 min at 4°C. The pellets were washed three times with cold 50 mM Tris buffer, and radioactivity was quantitated in a gamma counter. Results were analyzed by GRAPHPAD PRISM software.
Intestinotrophic activities of various peptide analogs were determined by assessment of small bowel weight as described (5), after 14-day treatments with 2.5 g of test peptide or PBS (vehicle-treated control) administered twice daily. Activity was defined as follows: active, small bowel wet weight 40-70% greater than in vehicle-treated control animals; partially active, 20-40% greater than controls; inactive, less than 20% greater than controls.
RNAse Protection Assay. A fragment of GLP-2R cDNA was subcloned into pBluescript (Stratagene) for in vitro transcription with T3 or T7 RNA polymerases. The probe, called F1, spanned nucleotides encoding amino acids Met-1 3 Arg-210. RNase protection assay was carried out essentially as described (6), using 50 g of total RNA from adult rat tissues or 50 g of yeast tRNA (negative control) or tRNA spiked with a known copy number of sense-strand cRNA (for standard curve construction). Each sample was hybridized with 100,000 cpm of [ 32 P]CTP-labeled antisense cRNA and then digested with RNases T1 (140 units͞ml) and A (8 g͞ml) at 30 C for 1 hr. The deproteinized, ethanol-precipitated probe was run on a 5% sequencing gel and analyzed after PhosphorImaging (Molecular Dynamics) with IMAGEQUANT software. RNA copy number was calculated by interpolation relative to the standard curve after taking the lengths and specific activities of undigested and digested probes into account. A second RNase probe from a different region of the GLP-2R cDNA was used to confirm the quantitative results (data not shown).
RESULTS AND DISCUSSION
GLP-2 and the peptide hormones GLP-1, glucagon, and GIP have closely related amino acid sequences (7) . Similarly, the sequences of cloned receptors for the latter three peptides form a cluster within the parathyroid hormone receptor-like GPCRs family B (8) (9) (10) (11) , suggesting that the GLP-2 receptor might also be found within this subfamily. Initial attempts at GLP-2 receptor cloning by conventional screening of cDNA libraries at low stringency with a combination of GLP-1 and glucagon receptor cDNA probes were not successful. Accordingly, we next used a combined approach of reverse transcription-PCR and hybridization screening followed by expression analysis of candidate cDNAs. As described in Methods and Materials, this strategy resulted in the isolation of a 2,537-bp rat GLP-2R cDNA insert encoding a 550-aa putative family B GPCR (Fig. 1) . Hydropathy analysis of the GLP-2R amino acid sequence revealed a typical 7-transmembrane topology plus a hydrophobic amino-terminal signal peptide (data not shown). The GLP-2R gene product belongs to the GLP-1͞glucagon͞ GIP receptor gene subfamily. Conserved features include a possible signal-peptide cleavage site between Val-64 and Thr-65, potential N-glycosylation sites within the amino-terminal putative extracellular domain, and six cysteine residues conserved in the mature GLP-1, GIP, and glucagon receptor amino-terminal domains (Fig. 1) . Two putative alternative translation initiation codons, Met-1 and Met-42, were found amino-terminal to the first transmembrane domain in the rat GLP-2R. Functional analysis of Met-1 and Met-42 sitedirected mutants showed they were functionally identical (unpublished results), consistent with signal-peptide removal predicted to yield an identical 486-aa mature polypeptide. Overlapping regions of the hypothalamus and duodenum͞ jejunum cDNA clones encoded homologous polypeptide fragments. Moreover, no evidence was obtained for differential splicing of intestinal GLP-2R RNA from an RNase protection assay employing two nonoverlapping probes derived from GLP-2R cDNA, which together spanned 387 of the 550 GLP-2R codons (data not shown). Additionally, sequencing of the full-length human GLP-2R cDNAs confirmed the identity of hypothalamic and gastrointestinal GLP-2Rs (Fig. 1) .
To assess whether the predicted GLP-2R sequence encodes a functional GLP-2 receptor, a GLP-2R expression construct, p587-70, was transiently transfected into COS cells. Because related family B GPCRs show functional coupling to cAMP production mediated by the heterotrimeric G protein Gs, cAMP accumulation was measured after incubation with GLP-2. Treatment of GLP-2R-transfected COS cells with 1 nM GLP-2 resulted in a 4-fold rise in cAMP levels relative to untreated cells, approximately equal to the response seen with 10 M forskolin ( Fig. 2A) . Treatment with 10 nM GLP-1, glucagon, GIP, exendin-3, and seven other family B GPCR ligands did not induce cAMP production in p587-70-transfected cells. Control cells transfected with vector DNA alone failed to respond to any of the peptides tested, including GLP-2, though forskolin did induce cAMP production.
With a stable GLP-2R episomal expression cell line, rG2R, greater than 20-fold cAMP induction routinely was achieved with 1 or 10 nM GLP-2 (data not shown), confirming the potent induction of cAMP accumulation by GLP-2. In contrast, the nontransfected 293-EBNA cells showed no response to GLP-2. The EC 50 of the cAMP response to GLP-2 in rG2R cells was 0.58 nM (Fig. 2B) . The presence of saturable, specific, ligand-selective GLP-2-binding sites on these cells was shown by using a radioiodinated, C-terminally extended GLP-2 analog, 125 I-[Tyr-34]GLP-2 (Fig. 3A) . From Scatchard analysis of the saturation isotherms, a B max value of 1,839 fmol͞mg of protein and a K d of 0.57 nM were obtained for the radioligand. Mock-transfected cells showed no specific binding to the radioligand (data not shown). Competition-binding studies with rat GLP-2 revealed a high-affinity site (K i ϭ 0.06 nM) and a low-affinity site (K i ϭ 259 nM) (Fig. 3B) . In contrast, no high-affinity GLP-1 sites were observed in the transfected GLP-2R͞rG2R clone. K i values determined for GLP-1, glucagon, and GIP peptides were 928, 500, and 765 nM, respectively. Although the binding and Scatchard data may reflect, in part, a degree of receptor overexpression, the functional studies and binding data provide firm evidence for a cDNA that encodes a functional high-affinity, ligandselective GLP-2 receptor.
The human GLP-2R polypeptide showed 81.6% similarity to rat GLP-2R (Fig. 1) . Functional expression of the cloned human GLP-2R conferred a functional response to GLP-2 and the appearance of high-affinity ligand-binding sites on 293-EBNA cells, similar to data obtained with the rat GLP-2R (data not shown). Furthermore, the cloned human GLP-2 receptor exhibited the same profile of peptide-binding specificity ( Fig. 2 A and unpublished data) as the rat receptor. The gene encoding human GLP-2R was identified by screening an arrayed BAC library of human genomic DNA (Genome Systems, St. Louis), confirmed by sequencing, and mapped to chromosome 17p13.3 by fluorescence in situ hybridization analysis (data not shown).
A quantitative ribonuclease protection assay method was used to determine the tissue distribution of rat GLP-2R RNA because no signals were detected on multitissue Northern blots. GLP-2R RNA levels were highest in jejunum, followed by duodenum, ileum, colon, and stomach, whereas expression was undetectable in seven other tissues (Table 1 ). This expression pattern is clearly concordant with previously reported functional responses to GLP-2 in duodenum (12, 13) , jejunum, ileum (5, 12, 14, 15) , and colon (12, 16, 17) ; in contrast, no proliferative or histological changes were seen after GLP-2 treatment in spleen, heart, kidney, lung, or brain (18) . Thus, GLP-2R expression is detected in known GLP-2 target tissues. This observation, together with the functional data from Total RNA (50 g) from rat tissues or sense-strand cRNA standards was hybridized to radiolabeled antisense cRNA probes prepared in vitro from GLP-2R cDNA (F1) or actin cDNA. After RNase digestion as described in Methods and Materials, protected probe was precipitated, electrophoresed, and quantitated by PhosphorImage analysis relative to the standard curve obtained from sense-strand cRNA. RNA quantitation is expressed as copy number per g of total RNA. GLP-2R RNA copy number was detectable to a lower limit of 30,000 copies per 50 g sample, setting the limit of detection shown above for nongastrointestinal tissues. (Table 2) . Carboxylterminal extension analogs bound and activated GLP-2R and retained in vivo activity whereas those with amino-terminal extensions lost both activities. Analogs with blocked amino-or carboxyl-terminal residues displayed diminished in vivo activity and GLP-2R activation. Insertion of a Thr residue between GLP-2 residues 6 and 7 resulted in loss of activity in vivo and in vitro. Truncation of the carboxyl-terminus to a 29-residue peptide (analogous to glucagon) reduced but did not eliminate in vivo or in vitro activities. Interestingly, truncation of one or two aminoterminal residues abolished in vivo activity but did not completely eliminate binding or the GLP-2R cAMP response. Taken together, a clear correspondence was revealed between the structural requirements for GLP-2R binding and activation and the in vivo intestinotrophic activity of GLP-2, providing additional evidence that the GLP-2R isolated here and the intestinotrophic GLP-2 receptor mediating GLP-2 action in vivo are synonymous.
Enteroglucagon synthesis long has been associated with a humoral adaptive response to massive small bowel resection, in which hyperplasia and elongation of jejunal villi are seen (19) (20) (21) (22) . Proglucagon-derived GLP-2 is detectable in plasma from fasted rats and humans and rises 1.5-to 3.6-fold after feeding (23) . Moreover, the intestinotrophic efficacy of GLP-2 has been shown after administration by i.p., i.m., or s.c. routes (14) , as well as by coinfusion in parenterally fed rats (12) . Thus, it is likely that circulating GLP-2 mediates adaptive changes in the villusabsorptive area in the small intestine. The cloning and characterization of a GLP-2 receptor expressed in the gastrointestinal tract qualifies GLP-2, like GLP-1, glucagon, and GIP, as a bona fide endocrine hormone and should facilitate the discovery of novel pharmacologic agents with similar functional activity. The expression of GLP-2R in hypothalamus also raises the possibility of as yet undescribed role(s) for this intestinotrophic hormone in the central nervous system.
